AXON Sio Gene Therapies Inc

AXON INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Axovant Sciences Ltd. Investors

BENSALEM, Pa.--(BUSINESS WIRE)--

Law Offices of Howard G. Smith commences an investigation on behalf of Axovant Sciences Ltd. (“Axovant Sciences” or the “Company”) (NASDAQ: AXON) investors concerning the Company and its officers’ possible violations of federal securities laws.

On February 12, 2018, Axovant Sciences announced that Chief Executive Officer David Hung had resigned as CEO and from the Company’s board of directors. In addition the Company also announced that Marion McCourt, President and Chief Operating Officer had resigned, and Kate Falberg, Tony Vernon and Patrick Machado have resigned as members of the Company’s board of directors.

On this news, shares of Axovant Sciences dropped $0.41 or over 20%, to close at $1.50 on February 12, 2018, thereby injuring investors.

If you purchased Axovant Sciences securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

EN
14/02/2018

Underlying

AXONSio Gene Therapies Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sio Gene Therapies Inc

 PRESS RELEASE
Free
AXON Sio Gene Therap...

Sio Gene Therapies Announces First Patient Dosed in High-Dose Cohort o...

Sio Gene Therapies Announces First Patient Dosed in High-Dose Cohort of AXO-AAV-GM1 Clinical Trial in Patients with GM1 Gangliosidosis On-track to report topline results from low-dose cohort by end of 2020 NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that the first patient has been dosed in the high-dose cohort of the Phase 1/2 (“Stage 1”) study for Type I (infant...

December 2, 2020 1 EN
 PRESS RELEASE
Free
AXON Sio Gene Therap...

Sio Gene Therapies Appoints Gene Therapy Pioneer Guangping Gao, Ph.D.,...

Sio Gene Therapies Appoints Gene Therapy Pioneer Guangping Gao, Ph.D., as Chief AAV Scientific Advisor A pioneering researcher, Dr. Gao has made foundational contributions to the discovery of novel AAV vectors for gene therapyDr. Gao recently served as President of the American Society for Gene and Cell Therapy (ASGCT) and has been ranked as one of the top 20 translational researchers by Nature Biotechnology NEW YORK and RESEARCH TRIANGLE PARK, N.C., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to...

November 19, 2020 1 EN
 PRESS RELEASE
Free
AXON Sio Gene Therap...

Sio Gene Therapies Announces Corporate Updates and Financial Results f...

Sio Gene Therapies Announces Corporate Updates and Financial Results for Second Fiscal Quarter Ended September 30, 2020 Continued progress across pipeline of gene therapy programs, including recent IND clearance for AXO-AAV-GM2 in Tay-Sachs/Sandhoff diseasesCompleted rebranding to Sio Gene Therapies as part of corporate transformation aligning corporate structure and governance with current and future business activityCompany had $63.2 million of cash and cash equivalents as of September 30, 2020, with sufficient cash runway into Q4 2021 NEW YORK and RESEARCH TRIANGLE PARK, N.C., Nov. 13,...

November 13, 2020 1 EN
 PRESS RELEASE
Free
AXON Sio Gene Therap...

Axovant Gene Therapies Announces Name Change to Sio Gene Therapies

Axovant Gene Therapies Announces Name Change to Sio Gene Therapies Rebranding to Sio Gene Therapies to reflect an independent company with a scientific strategy focused on disease-modifying and curative genetic medicinesCompany’s common stock will trade on the NASDAQ under new ticker “SIOX” effective November 13, 2020 NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage gene therapy company developing innovative gene therapies for neurodegenerative diseases, today announced it will change its name to Sio Gene Therapies, Inc., effective ...

November 10, 2020 1 EN
 PRESS RELEASE
Free
AXON Sio Gene Therap...

Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 ...

Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff Diseases AXO-AAV-GM2 is the first investigational gene therapy to receive IND clearance in Tay-Sachs and Sandhoff diseasesRepresents Axovant’s second IND clearance for a gene therapy program in the last 12 months NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has lifted its clinical hold and cleared the Investigati...

November 9, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch